Skip to main content

Court Grants Temporary Stay On JUUL's Vape Products Ban

Court Grants Temporary Stay On JUUL's Vape Products Ban

Court Grants Temporary Stay On JUUL's Vape Products Ban

Introduction

Food and Drug Administration's (FDA) order to ban the sale of JUUL's e-cigarettes has been temporarily blocked by a federal court as the manufacturer has asked for additional time to file an appeal of the recent regulatory decision.

Earlier, FDA rejected the authorization of JUUL vaping products and asked the manufacturer to discontinue the sale and recall the products from the U.S. market, citing the long-term effects of teen vaping addiction.

JUUL introduced vape pens in a variety of flavors in 2015 with a design similar to a USB drive. This allowed the teens to hide their products and vaping habits from parents and school officials. Eventually, the e-cigarettes became popular among the teens, which increased the addiction problems throughout the nation.

The manufacturer's deceptive marketing through social media, and other mediums to lure the teens, additionally fueled the addiction crisis. These misleading strategies even led non-smokers to use vape pens. FDA issued a ban on the products to control the skyrocketing teen nicotine addiction rate.

JUUL denied the FDA's order and appealed the decision in the court. JUUL Lab’s Chief Regulatory Officer defended their products by stating that the products are compliant with the statutory standards that make the products appropriate for the protection of public health.

JUUL is even considering filing for Chapter 11 bankruptcy to deal with the ban as a majority of the revenue from the sale of the products for the manufacturer comes from the U.S.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

Purdue, Sacklers Agree to New $7.4B Opioid Settlement

Categories: Opioids

All 50 U.S. states, along with the District of Columbia and U.S. territories, have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

This deal addresses allegations that the company’s aggressive and…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!